LabCorp 2013 Annual Report Download - page 57

Download and view the complete annual report

Please find page 57 of the 2013 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 58

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58

Corporate Headquarters
358 South Main Street
Burlington, NC 27215
336-584-5171
Information Sources
Information about LabCorp is available from
the following Company sources:
Investor Relations Contact
Stephen Anderson
Vice President, Investor Relations
336-436-5076
Center for Molecular Biology and Pathology
800-345-4363
Center for Occupational Testing
800-833-3984
Center for Esoteric Testing
800-334-5161
Paternity/Identity
800-582-0077
LabCorp Drug Development Laboratory Services
877-788-8861
Website
www.labcorp.com
Transfer Agent
American Stock Transfer & Trust Company
Shareholder Services
6201 Fifteenth Avenue
Brooklyn, NY 11219
800-937-5449
www.amstock.com
Independent Registered
Public Accounting Firm
PricewaterhouseCoopers LLP
800 Green Valley Road, Suite 500
Greensboro, NC 27408
Annual Meeting
The annual meeting of shareholders will be
held at 9:00 a.m. EDT on May 14, 2014 at the
Paramount Theater, 128 East Front Street,
Burlington, NC 27215.
Form 10-K
Copies of Form 10-K as fi led with the Securities
and Exchange Commission are available
without cost to shareholders by writing to:
Laboratory Corporation of America Holdings
Investor Relations Department
358 South Main Street
Burlington, NC 27215
To download this Annual Report or the
Company’s Proxy Statement, visit our
website at: www.labcorp.com.
Safe Harbor
Forward-looking statements in this annual
report are subject to change based on various
important factors, including without limitation,
competitive actions in the marketplace and
adverse actions of governmental and other
third-party payers. Actual results could diff er
materially from those suggested by these forward-
looking statements. Further information on
potential factors which could aff ect the Company’s
fi nancial results is included in the Company’s
Form 10-K for the year ended December 31, 2013,
and subsequent fi lings.
Common Stock
The Company’s common stock, par value
$0.10 per share (the “Common Stock”), trades
on the New York Stock Exchange (“NYSE”) under
the symbol “LH.” The following table sets forth
for the calendar periods indicated the high and
low sales prices for the Common Stock reported
on the NYSE Composite Tape.
2013 2012
High Low High Low
1Q $ 91.84 $85.80 $93.30 $85.58
2Q $101.69 $89.68 $94.33 $81.56
3Q $101.92 $95.36 $95.30 $83.50
4Q $108.00 $87.01 $94.30 $82.15
Corporate Governance, Code of
Business Conduct and Ethics
The Company’s Corporate Governance Guidelines,
the Charters of its Audit Committee, Compensation
Committee, Quality and Compliance Committee,
and Nominating and Corporate Governance
Committee as well as the Company’s Code of
Business Conduct and Ethics are available on
the Company’s website at www.labcorp.com.
You can also obtain a hard copy of these
documents, without charge, upon written
request to Stephen Anderson, Laboratory
Corporation of America Holdings, 358 South
Main Street, Burlington, NC 27215.
Shareholder and Company Information
BOARD OF DIRECTORS
David P. King
Chairman and Chief Executive Offi cer
Kerrii B. Anderson 1,2
Former Chief Executive Offi cer and
President of Wendy’s International, Inc.
Jean-Luc Bélingard 2,3
Chairman, bioMérieux S.A.;
retired Chairman and CEO, Ispen S.A.
Garheng Kong, M.D., Ph.D.
General Partner at Sofi nnova HealthQuest
Wendy E. Lane 1,4
Chairman of Lane Holdings, Inc.,
an investment fi rm
Robert E. Mittelstaedt, Jr. 1,4
Dean Emeritus of the W. P. Carey School
of Business at Arizona State University
Peter M. Neupert 2,4
Operating Partner at Health Evolution Partners
Arthur H. Rubenstein, MBBCh 1,3
Professor of Medicine
University of Pennsylvania
Perelman School of Medicine
Adam H. Schechter 1,2
Executive Vice President of Merck & Co., Inc. and the
President of Merck’s Global Human Health Division
M. Keith Weikel, Ph.D. 2,3
Former Senior Executive Vice President and
Chief Operating Offi cer of HCR Manor Care, Inc.
R. Sanders Williams, M.D. 1,3
President of The J. David Gladstone Institutes
and Proff essor of Medicine at The University of
California San Francisco
Committees:
1 Audit
2 Compensation
3 Quality and Compliance
4 Nominating and Corporate Governance
Management Team
David P. King, Chairman and Chief Executive Offi cer
James T. Boyle, Executive Vice President and
Chief Operating Offi cer
William B. Hayes, Executive Vice President and
Chief Financial Offi cer
Lance V. Berberian, Senior Vice President and
Chief Information Offi cer
Mark E. Brecher, M.D., Senior Vice President and
Chief Medical Offi cer
F. Samuel Eberts III, Senior Vice President and
Chief Legal Offi cer
Adam T. Feinstein, Senior Vice President,
Corporate Development & Strategic Planning
Lisa Hoffman Starr, Senior Vice President,
Human Resources